Nonarteritic anterior ischemic optic neuropathy, often called NAION, is a sudden, painless drop in vision caused by reduced blood flow to the optic nerve head. Patients who have already had NAION in one eye worry most about the fellow eye. A large-database analysis presented at the American Academy of Ophthalmology 2026 meeting looked at whether glucagon-like peptide-1 (GLP-1) receptor agonists change when that second event happens.
What the researchers compared
Ashley Tin and colleagues from Carle Illinois College of Medicine studied early fellow-eye events (1 to 6 months) versus late events (36 to 60 months) in 1,440 GLP-1 receptor agonist users and 20,713 nonusers. They stratified by the eras before and after these medicines became widely used.
What they found
- Among people who had a sequential NAION event, 69.5% of GLP-1 users had that second-eye event within six months, compared with 52% of nonusers.
- The relative risk for an early versus late second-eye event was 2.63 in users versus nonusers.
- The pattern was consistent across the pre- and post-GLP-1 eras.
- GLP-1 users also had higher average hemoglobin A1c than nonusers, so diabetes control may partly explain the difference.
The authors described the result as an association that matched what they had seen clinically. It does not prove that Ozempic, Wegovy, Mounjaro, or related medicines cause NAION, and it does not tell us the absolute risk for any one patient.
What this means in the exam room
- Sudden vision loss, a dark shadow, or new field loss needs same-day urgent eye care.
- If you have already had NAION, tell both your eye doctor and the clinician who manages your metabolic medicines about the history.
- Do not stop a prescribed GLP-1 medicine on your own; discuss risks and benefits with the prescribing clinician.
- Blood pressure, sleep apnea, and other vascular factors also matter for optic-nerve health.
Our role
At Khanna Vision Institute we evaluate sudden vision changes promptly and coordinate with retina and neuro-ophthalmology colleagues when needed. For more reading on how retinal and choroidal conditions are explained in plain language, see pieineye.com.
Source: AAO: Sequential nonarteritic anterior ischemic optic neuropathy occurs earlier with GLP-1 receptor agonist exposure (Medical Xpress / HealthDay (AAO 2026 presentation), 10/21/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.